Express Mail Label No.: ED 798634874 US Attorney Docket No.: 100870-1P US

### JC06 Rec'd PCT/PTO 21 SEP 2005

Approved for use through 3/31/2007. OMB 0651-0021 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL LETTER TO THE UNITED STATES

ATTORNEY'S DOCKET NUMBER 100870-1P US

	DESIGNATED/ELECTED CERNING A SUBMISSIC	U.S. APFLICATIONS (No. 10 No. 3 Sep 37 CFR 1.5)				
	TIONAL APPLICATION NO. CT/GB2004/001119	INTERNATIONAL FILING DATE March 16, 2004	PRIORITY DATE CLAIMED  March 20, 2003			
	TITLE OF INVENTION ANTIBACTERIAL 1,3-OXAZOLIDIN-2-ONE DERIVATIVES					
APPLICAN	APPLICANT(S) FOR DO/EO/US Gravestock et al					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:						
1. X	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.					
2. 🔲 т	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.					
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4. 🗓 1	The US has been elected (Article 31).					
5. X	A copy of the International Application	n as filed (35 U.S.C. 371(c)(2))				
	a. is attached hereto (required	only if not communicated by the Internation	nal Bureau).			
	b. $\overline{\mathbf{X}}$ has been communicated by	the International Bureau.				
	c. is not required, as the applie	cation was filed in the United States Receivi	ng Office (RO/US).			
6.	An English language translation of the	e International Application as filed (35 U.S.C	C. 371(c)(2)).			
	a. is attached hereto.					
	b. has been previously submit	tted under 35 U.S.C. 154(d)(4).				
7. X	Amendments to the claims of the Inte	rnational Application under PCT Article 19 (	35 U.S.C. 371(c)(3))			
	a. are attached hereto (requi	red only if not communicated by the Internal	tional Bureau).			
	b. have been communicated	by the International Bureau.				
	c. have not been made; how	ever, the time limit for making such amendn	nents has NOT expired.			
	d. $\overline{X}$ have not been made and $v$	vill not be made.				
8.	An English language translation of the	e amendments to the claims under PCT Art	icle 19 (35 U.S.C. 371(c)(3)).			
9. X	An oath or declaration of the inventor	(s) (35 U.S.C. 371(c)(4)).				
10.	An English language translation of the Article 36 (35 U.S.C. 371(c)(5)).	e annexes of the International Preliminary E	xamination Report under PCT			
Items 11 to 20 below concern document(s) or information included:						
11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.				
12.	An assignment document for recording	g. A separate cover sheet in compliance wi	th 37 CFR 3.28 and 3.31 is included.			
13. X	A preliminary amendment.					
<sub>14.</sub> X	An Application Data Sheet under 37 G	CFR 1.76.				
15. 🔲	A substitute specification.					
16. X	A power of attorney and/or change of	address letter.				
17. 🔲	A computer-readable form of the sequence	uence listing in accordance with PCT Rule 1	3ter.2 and 37 CFR 1.821- 1.825.			
18. 🔲	A second copy of the published Interr	national Application under 35 U.S.C. 154(d)	(4).			
19. 🗀	A second copy of the English language	ge translation of the international application	under 35 U.S.C. 154(d)(4).			

## JC20 Rec'd PCT/PTO 21 SEP 2005

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Not yet assigned			PCT/GB200		100870-1P US	
20. Other items or International Sea		5 pages);	International Prelin	ninary Report o	n Patentability (8 sh	ueets)
The following fe	es have been sub	mitted			CALCULATIONS	PTO USE ONLY
21. X Basic national fee (37 CFR 1.492(a))					\$ 300.00	
22. X Examination i	fee (37 CFR 1.492	(c))				
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0  All other situations\$200					\$ 200.00	
23. X Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)				\$ 400.00		
TOTAL	OF 21, 22 and 23	_			900.00	
Additional fee for spe sequence listing i electronic medium	ecification and draw in compliance with m) (37 CFR 1.492(	vings filed ir 37 CFR 1.8 j)).	n paper over 100 sheets (e) 321(c) or (e) or computer pr f paper or fraction thereof.	ccluding ogram listing in an		
Total Sheets Extra S			ditional 50 or fraction to a whole number)	RATE		
65 <sub>- 100 =</sub>	/50 =			x \$250	\$ 0.00	l
			ee, examination fee, or the (37 CFR 1.492(h)).	oath or declaration	\$	
CLAIMS	NUMBER FILE	D	NUMBER EXTRA	RATE	\$	
Total claims	14	- 20 =		x \$50	\$	
Independent claims	5	- 3 =	2	x \$200	\$ 400.00	
MULTIPLE DEPENDENT	CLAIM(S) (if appl	icable)		+ \$360	\$	
			TOTAL OF ABOVE	CALCULATIONS =	\$ 0.00	
Applicant claims sma	all entity status. Se	e 37 CFR 1	.27. Fees above are reduc	ed by 1/2.		
				SUBTOTAL =	\$ 1,300.00	
Processing fee of \$130.00 claimed priority date (37.00)	_	English tra	nslation later than 30 mont	hs from the earliest +	\$	
			TOTAL	NATIONAL FEE =	\$	1,300.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	0.00	
			TOTAL F	EES ENCLOSED =	\$	1,300.00
					Amount to be refunded:	\$
					Amount to be charged	\$

10/550039
PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

_		IC20 Rec'd PENALO AL SEP 2003		
a. 🔝	A check in the amount of \$ to cover	the above fees is enclosed.		
b. X	Please charge my Deposit Account No. $50-3231$ in the amount of \$ $1,300.00$ to cover the above fees. A duplicate copy of this sheet is enclosed.			
c. X	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No50-3231 A duplicate copy of this sheet is enclosed.			
d. 🔲	Fees are to be charged to a credit card. <b>WARNING</b> : Information on this form may become public. <b>Credit card information should not be included on this form</b> . Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.				
	ALL CORRESPONDENCE TO: omer No.: 44992	SIGNATURE  Heidi M. Berven  NAME  48,951  REGISTRATION NUMBER		

Express Mail Label No.: ED 908733412 US

Attorney Docket No.: 100820-1P US

1 of 1

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock et at	Filed: Herewith		
Application No.: Not yet assigned	Attorney Docket No.: 100870		
PCT Application No.: PCT/GB2004/001119	Examiner: Not yet assigned		
Title: ANTIBACTERIAL 1,3-OXAZOLIDIN-2-ONE DERIVIATIVES			

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

#### **COMMUNICATION SUBMITTED WITH PTO/SB/64** PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. § 1.137(b)

As provided in PTO/SB/64 attached herewith, Form PTO-1390 and the relevant fee for the captioned application was due for submission to the United States PTO on September 20, 2005. Form PTO-1390 and the relevant fee were unintentionally filed on September 21, 2005. Applicants hereby respectfully request revival of the application and reinstatement of Applicants' priority rights under 37 C.F.R. §1.137(b), in light of PCT Rule 82.2.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100870.

Respectfully submitted,

Name:

Heidi Berven

Dated:

Sept 23, 2005 48,951

Reg. No.:

Phone No.: 781-839-4336

Global Intellectual Property, Patents,

AstraZeneca R&D Boston,

35, Gatehouse Drive,

Waltham, MA 01760

10/550039 JC09 Rec'd PC 770 23 SEP 2005

#### Addendum

- 1. 1500. Please charge Deposit Account No. 50-3231, referencing Attorney Docket No. 100870-1P-US
- 2. Septemer 21, 2005. The fee and 1390 form were due on September 20, 2005. The fee and form were unintentionally filed on September 21, 2005.